FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to ...

Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI(TM) (relacorilant), which is indicated in ...

The FDA has approved Lifyorli (relacorilant) plus Abraxane for certain platinum‑resistant ovarian cancer patients, offering a ...

FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic ...

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high therapeutic efficacy. However, many of these compounds possess properties that ...

Shares of Corcept Therapeutics (NASDAQ:CORT) surged about 40% on Wednesday after the U.S. Food and Drug Administration (FDA) ...

After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical ...

By Kamal Choudhury March 25 (Reuters) - Corcept Therapeutics shares jumped more than 23% to a near two-month high on ...

Median overall survival (OS) and progression-free survival (PFS) in uterine carcinosarcoma (UCS) both improved with paclitaxel and carboplatin as compared with a standard-of-care regimen, a randomized ...

Long-term data from the Veterans Health Administration (VHA) are in line with the conclusions of several recent trials and registries that dispute the existence of an increased mortality signal with ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in ...